PCM
MXCT icon

Prelude Capital Management’s MaxCyte MXCT Stock Holding History

Prelude Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,700
Closed -$41.6K – 1435
2024
Q3 		$41.6K Buy
+10,700
New +$45.1K ﹤0.01% 1220
2023
Q4 		– Sell
-16,540
Closed -$51.6K – 1254
2023
Q3 		$51.6K Buy
+16,540
New +$66.5K ﹤0.01% 1043

Other funds holding MXCT

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
RGI
River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's MXCT Position: Q4 2024 in Review

Prelude Capital Management sold out of MaxCyte (MXCT) in Q4 2024, closing a stake of 10,700 shares — an estimated $41.6K sold.

Prelude Capital Management first reported a position in MXCT in Q3 2023 and held it in 2 quarters. The position peaked at $51.6K in Q3 2023. 119 funds tracked by Wall St. Rank hold MXCT as of Q4 2024.

  • Prelude Capital Management reported no remaining MaxCyte position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 10,700 MaxCyte shares in Q4 2024, an estimated $41.6K.
  • Prelude Capital Management first reported a position in MaxCyte in Q3 2023 and held it in 2 quarters.
  • Prelude Capital Management's MaxCyte position peaked at $51.6K in Q3 2023.
  • 119 funds tracked by Wall St. Rank held MaxCyte as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.